FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:2249-2251 May 21, 2009 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mega, J. L. Related Article by Simon, T. PubMed Citation

To the Editor: On the basis of the results of a genetic association study (Jan. 22 issue),¹ Mega et al. conclude that reduced-function variants of the CYP2C19 allele are responsible for lower plasma levels of the active metabolite of clopidogrel; these lower levels lead to decreased platelet inhibition and thereby increase cardiovascular risk. However, no direct evidence of the causal involvement of the cytochrome P-450 enzyme CYP2C19 in the biotransformation of clopidogrel to its active metabolite is presented.

To test the hypothesis of Mega et al., we incubated clopidogrel, the inactive metabolic intermediate 2-oxo-clopidogrel,² and the known CYP2C19 substrate omeprazole³ . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.